Prime editing enables drug-controllable T-cell therapies with clinical immunosuppression.
A multiplex prime-editing platform is developed that converts commonly used immunosuppressive drugs into tools for in vivo control of T-cell therapies via defined, pathway-specific drug resistance, enabling selective in vivo modulation in settings where immunosuppression cannot be withdrawn.
E. Bandala-Sanchez, Emma V. Petley, K. Ramsay et al.
· Blood · 0 citations